Status:
TERMINATED
Stress Echocardiography Study With Regadenoson
Lead Sponsor:
Gilead Sciences
Conditions:
Heart Disease
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.
Eligibility Criteria
Inclusion
- Patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress
- Patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress
Exclusion
- Any condition precluding the safe administration of dobutamine, dipyridamole or SonoVue for echocardiography
- Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00907764
Start Date
April 1 2009
End Date
April 1 2010
Last Update
January 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwick Park Hospital
Harrow, United Kingdom, HA1 3UJ